NeoPharm CO. LTD (092730) — Financial Flexibility Index
NeoPharm CO. LTD (092730) has a Financial Flexibility Index of 0.33x as of September 2025. Free cash flow of ₩6.32 Billion (operating CF ₩5.88 Billion minus capex ₩446.60 Million) represents 0% of total liabilities (₩18.97 Billion). Check NeoPharm CO. LTD strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NeoPharm CO. LTD Financial Flexibility Index (2012–2024)
Historical Financial Flexibility Index trend for NeoPharm CO. LTD across 11 annual periods. See how liquid is NeoPharm CO. LTD's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for NeoPharm CO. LTD (2012–2024)
Year-by-year free cash flow to debt coverage for NeoPharm CO. LTD. For the full company profile including market capitalisation, see NeoPharm CO. LTD (092730) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.40x | ₩21.71 Billion | ₩18.63 Billion | ₩15.56 Billion | ▼ -44.8% |
| 2023 | 2.53x | ₩44.09 Billion | ₩23.26 Billion | ₩17.43 Billion | ▲ +75.2% |
| 2022 | 1.44x | ₩18.97 Billion | ₩18.16 Billion | ₩13.14 Billion | ▼ -14.0% |
| 2021 | 1.68x | ₩22.00 Billion | ₩21.68 Billion | ₩13.10 Billion | ▲ +47.6% |
| 2020 | 1.14x | ₩17.36 Billion | ₩17.07 Billion | ₩15.26 Billion | ▼ -22.8% |
| 2019 | 1.47x | ₩25.13 Billion | ₩19.22 Billion | ₩17.05 Billion | ▲ +10.9% |
| 2018 | 1.33x | ₩18.12 Billion | ₩16.18 Billion | ₩13.64 Billion | ▲ +5.0% |
| 2017 | 1.27x | ₩11.53 Billion | ₩10.65 Billion | ₩9.11 Billion | ▼ -4.9% |
| 2016 | 1.33x | ₩10.56 Billion | ₩9.16 Billion | ₩7.94 Billion | ▲ +50.5% |
| 2015 | 0.88x | ₩6.88 Billion | ₩6.09 Billion | ₩7.79 Billion | ▲ +406.0% |
| 2012 | 0.17x | ₩736.81 Million | ₩564.34 Million | ₩4.22 Billion | — |